HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that members of its senior leadership team will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024, at 9:00 a.m. ET, and will host investor meetings in New York, NY. A live webcast and a replay of the presen.
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced the submission of a protocol to its open Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for a Phase 2 study evaluating tibulizumab, a humanized tetravalent bispecific dual antagonist antibody designed to neutralize both IL-17A.
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today shared supportive data from a Phase 1 study evaluating its lead candidate, tibulizumab (ZB-106), for the treatment of Sjogren's syndrome. These data, along with preclinical data supporting further development of tibulizumab in rheumatoid arthritis (RA), were presented at the Annual European Co.
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced it will present data from its tibulizumab (ZB-106) program exploring the clinical potential of the dual-pathway antibody in Sjogren's syndrome and rheumatoid arthritis (RA) at EULAR 2024, June 12-15 in Vienna. “We are excited to present translational data from our tibulizumab (ZB-106.
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that members of senior management will participate in two investor conferences in June. Conference Details: Event: Jefferies Global Healthcare Conference Details: Michael Howell, Ph.D., Chief Scientific Officer and Head of Translational Medicine, will participate in one-on-one meetin.
The average price targets from Wall Street analysts suggest a potential upside of 248.8% for Zura Bio Limited (ZURA). Although the reliability of this metric is uncertain, the positive trend in earnings estimate revisions could lead to an increase in the stock's value.
Zura Bio Limited (ZURA) could see an increase in its stock price due to increasing confidence in its earnings potential, as evidenced by its upgrade to a Zacks Rank #2 (Buy).
Zura Bio's lead therapy is ZB-106. The company plans to start two phase 2 trials for the therapy.
Zura Bio (NASDAQ: ZURA ) stock is on the move Thursday following the clinical-stage biotechnology company's recent public debut. Zura Bio went public on Tuesday after completing its special purpose acquisition company (SPAC) merger with JATT Acquisition Corp. Afterward, the company's shares saw a massive spike in price during trading on Wednesday.